Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Sleep spindles in Parkinson's disease may predict the development of dementia.

Latreille V, Carrier J, Lafortune M, Postuma RB, Bertrand JA, Panisset M, Chouinard S, Gagnon JF.

Neurobiol Aging. 2015 Feb;36(2):1083-90. doi: 10.1016/j.neurobiolaging.2014.09.009. Epub 2014 Sep 18.

PMID:
25442116
2.

Physical activity in advanced Parkinson's disease: impact of subthalamic deep brain stimulation.

Daneault JF, Sadikot AF, Barbat-Artigas S, Aubertin-Leheudre M, Jodoin N, Panisset M, Duval C.

J Parkinsons Dis. 2015;5(1):85-93. doi: 10.3233/JPD-140426.

PMID:
25361545
3.

Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO).

Panisset M, Chen JJ, Rhyee SH, Conner J, Mathena J; STACCATO study investigators.

Pharmacotherapy. 2014 Dec;34(12):1250-8. doi: 10.1002/phar.1500. Epub 2014 Oct 14.

PMID:
25314256
4.

Increased Prevalence of Non-motor Symptoms in Essential Tremor.

Lacerte A, Chouinard S, Jodoin N, Bernard G, Rouleau GA, Panisset M.

Tremor Other Hyperkinet Mov (N Y). 2014 Sep 2;4:162. doi: 10.7916/D82V2D91. eCollection 2014.

5.

Predictors of dementia in Parkinson disease: a prospective cohort study.

Anang JB, Gagnon JF, Bertrand JA, Romenets SR, Latreille V, Panisset M, Montplaisir J, Postuma RB.

Neurology. 2014 Sep 30;83(14):1253-60. doi: 10.1212/WNL.0000000000000842. Epub 2014 Aug 29.

6.

Subthalamic stimulation improves motor function but not home and neighborhood mobility.

Daneault JF, Duval C, Barbat-Artigas S, Aubertin-Leheudre M, Jodoin N, Panisset M, Sadikot AF.

Mov Disord. 2014 Dec;29(14):1816-9. doi: 10.1002/mds.25911. Epub 2014 May 22.

PMID:
24849309
7.

Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease.

Moonen AJ, Wijers A, Leentjens AF, Christine CW, Factor SA, Juncos J, Lyness JM, Marsh L, Panisset M, Pfeiffer R, Rottenberg D, Serrano Ramos C, Shulman L, Singer C, Slevin J, McDonald W, Auinger P, Richard IH.

Parkinsonism Relat Disord. 2014 Jun;20(6):644-6. doi: 10.1016/j.parkreldis.2014.02.025. Epub 2014 Mar 18.

PMID:
24679737
8.

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K.

JAMA Neurol. 2014 May;71(5):543-52. doi: 10.1001/jamaneurol.2014.131.

PMID:
24664227
9.

Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?

Daneault JF, Carignan B, Sadikot AF, Panisset M, Duval C.

BMC Med. 2013 Mar 20;11:76. doi: 10.1186/1741-7015-11-76. Review.

10.

Exome sequencing identifies FUS mutations as a cause of essential tremor.

Merner ND, Girard SL, Catoire H, Bourassa CV, Belzil VV, Rivière JB, Hince P, Levert A, Dionne-Laporte A, Spiegelman D, Noreau A, Diab S, Szuto A, Fournier H, Raelson J, Belouchi M, Panisset M, Cossette P, Dupré N, Bernard G, Chouinard S, Dion PA, Rouleau GA.

Am J Hum Genet. 2012 Aug 10;91(2):313-9. doi: 10.1016/j.ajhg.2012.07.002. Epub 2012 Aug 2.

11.

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.

Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer R, Rottenberg D, Slevin J, Elmer L, Press D, Hyson HC, McDonald W; SAD-PD Study Group.

Neurology. 2012 Apr 17;78(16):1229-36. doi: 10.1212/WNL.0b013e3182516244. Epub 2012 Apr 11.

12.

Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson's disease: a prospective study.

Postuma RB, Bertrand JA, Montplaisir J, Desjardins C, Vendette M, Rios Romenets S, Panisset M, Gagnon JF.

Mov Disord. 2012 May;27(6):720-6. doi: 10.1002/mds.24939. Epub 2012 Feb 9.

PMID:
22322798
13.

Glucocerebrosidase mutations in a French-Canadian Parkinson's disease cohort.

Noreau A, Rivière JB, Diab S, Dion PA, Panisset M, Soland V, Jodoin N, Langlois M, Chouinard S, Dupré N, Rouleau GA.

Can J Neurol Sci. 2011 Sep;38(5):772-3. No abstract available.

PMID:
21856586
14.

LINGO1 variants in the French-Canadian population.

Bourassa CV, Rivière JB, Dion PA, Bernard G, Diab S, Panisset M, Chouinard S, Dupré N, Fournier H, Raelson J, Belouchi M, Rouleau GA.

PLoS One. 2011 Jan 11;6(1):e16254. doi: 10.1371/journal.pone.0016254.

15.

Chylomicron retention disease: dystonia as a new clinical feature.

Bernard G, Panisset M, Sadikot AF, Chouinard S.

Mov Disord. 2010 Aug 15;25(11):1755-6. doi: 10.1002/mds.23165. No abstract available.

PMID:
20589877
16.

Central pontine and extrapontine myelinolysis: from epileptic and other manifestations to cognitive prognosis.

Odier C, Nguyen DK, Panisset M.

J Neurol. 2010 Jul;257(7):1176-80. doi: 10.1007/s00415-010-5486-7. Epub 2010 Feb 11.

PMID:
20148334
17.

Executive functions in frontotemporal dementia and Lewy body dementia.

Johns EK, Phillips NA, Belleville S, Goupil D, Babins L, Kelner N, Ska B, Gilbert B, Inglis G, Panisset M, de Boysson C, Chertkow H.

Neuropsychology. 2009 Nov;23(6):765-77. doi: 10.1037/a0016792.

PMID:
19899835
18.

Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson's disease.

Gagnon JF, Vendette M, Postuma RB, Desjardins C, Massicotte-Marquez J, Panisset M, Montplaisir J.

Ann Neurol. 2009 Jul;66(1):39-47. doi: 10.1002/ana.21680.

PMID:
19670440
19.

Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.

Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A; FIRST-STEP Study Group.

Mov Disord. 2009 Mar 15;24(4):541-50. doi: 10.1002/mds.22343.

PMID:
19058133
20.

Impact of standard of care for psychosis in Parkinson disease.

Thomsen TR, Panisset M, Suchowersky O, Goodridge A, Mendis T, Lang AE.

J Neurol Neurosurg Psychiatry. 2008 Dec;79(12):1413-5. doi: 10.1136/jnnp.2008.153163. No abstract available.

PMID:
19010958
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk